Cell and Gene Therapy Today—February 5, 2026
This week's Cell and Gene Therapy updatehighlights key regulatory actions,…
Lucid Diligence Brief: AstraZeneca buys remaining China rights to AbelZeta’s GPC3-armored CAR-T
Lucid Diligence Brief: AstraZeneca buys remaining China rights to AbelZeta’s…
Lucid Diligence Brief: Cytotheryx $60 million Series A in liver cell therapy
Lucid Diligence Brief: Cytotheryx $60 million Series A in liver cell therapy…
Neuroscience Today—January 14, 2026
Today's neuroscience weekly update spotlights major advances spanning cell and…
Lucid Diligence Brief: Vyriad $25M Series B to take in-vivo CAR-T into clinic
Lucid Diligence Brief: Vyriad $25M Series B to take in-vivo CAR-T into clinic…
Cell and Gene Therapy Today—December 18, 2025
This week’s Cell & Gene Therapy update highlights major developments,…
Lucid Diligence Brief: Imugene onCARlytics Carteyva collaboration
Lucid Diligence Brief: Imugene onCARlytics Carteyva collaboration Professional…
Lucid Diligence Brief: Aspen Neuroscience $115M Series C
Lucid Diligence Brief: Aspen Neuroscience $115M Series C Professional audiences…
Lucid Diligence Brief: Tempest Therapeutics and Factor Bioscience dual-CAR T deal
Lucid Diligence Brief: Tempest Therapeutics and Factor Bioscience dual-CAR T…
Hematology Today—November 10, 2025
This week’s Hematology update spotlights fresh breakthroughs, regulatory…
Lucid Diligence Brief: Wa’ed Ventures Kure Cells pre-Series A
Lucid Diligence Brief: Wa’ed Ventures Kure Cells pre-Series A Professional…
Lucid Diligence Brief: Bristol Myers Squibb's acquisition of Orbital Therapeutics
Lucid Diligence Brief: Bristol Myers Squibb's acquisition of Orbital…